An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)

CompletedOBSERVATIONAL
Enrollment

215

Participants

Timeline

Start Date

February 13, 2017

Primary Completion Date

August 2, 2018

Study Completion Date

March 7, 2019

Conditions
Primary Mitochondrial Disease
Trial Locations (33)

10032

Columbia University Medical Center, New York

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

44195

Cleveland Clinic, Cleveland

44308

Akron Children's Hospital, Akron

46026

Neurology Department Hospital Universitari i Politecnic La Fe, Valencia

53105

University Hospital of Bonn, Bonn

56126

Dipartimento Ambientale di Neuroscienze, Roma

77030

Baylor College of Medicine, Houston

The University of Texas Health Science Center, Houston

80045

Children's Hospital Colorado, Aurora

80336

Klinikim der Universitat Muchen, Friedrich-Baur Institute, Munich

84132

University of Utah Hospital, Salt Lake City

92093

University of California San Diego, La Jolla

94304

Stanford Universtity, Palo Alto

98105

Seattle Children's Hospital, Seattle

98125

Azienda Ospedaliero Universitaria Policlinico G. Martino, Messina

02114

Massachusetts General Hospital, Boston

19104'

The Children's Hospital of Philadelphia, Philadelphia

Unknown

Calvary Health Care Bethlehem, Caulfield South

Royal North Shore Hospital, St Leonards

University of Calgary Metabolic Disease Clinica, Calgary

McMaster University Medical Center, Hamilton

Adult Metabolic Diseases Clinic, Vancouver

University of Copenhagen, Copenhagen

Institute of Genomic Medicine and Rare Disorders, Budapest

IRCCS Institute of Neurological Sciences of Bolgna, Bellaria Hospital, Bologna

ASST Spedali Civili di Brescia, Brescia

Istituto Nazionale Neurologico Carlo Besta, Milan

Ospedale Pediatrico Bambin Gesu, Roma

Hospital Universitario 12 de Octubre, Madrid

MRC Centre for Neuromuscular Diseases, London

Royal Victoria Infirmary, Newcastle upon Tyne

00168

Istituto di Neurologia, Fondazione Policlinico Universitario A. Gemelli, Roma

All Listed Sponsors
lead

Stealth BioTherapeutics Inc.

INDUSTRY

NCT03048617 - An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300) | Biotech Hunter | Biotech Hunter